Figure 2 | Scientific Reports

Figure 2

From: Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS

Figure 2

Foxa1 knockout in the setting of Upk2-driven expression of mutant HRAS results in regression of urothelial hyperplasia with a cystic phenotype. (A) Genetic control (UBC-CreERT2 alone) mice, (B) UBC-CreERT2/Foxa1loxp and (C) UBC-CreERT2/Foxa1loxp/loxp mice were injected with tamoxifen once daily for five days and then sacrificed 3 months later. Note presence of squamous metaplasia in UBC-CreERT2/Foxa1loxp/loxp mice (panel c) as previously reported. All Upk2-HRAS* mice were similarly injected with tamoxifen and sacrificed 3 months later. (D) Upk2-HRAS* with minimal cysts, (E) Upk2-HRAS*/UBC-CreERT2/Foxa1loxp mice with increased cyst presence, and (F) Upk2-HRAS*/UBC-CreERT2/Foxa1loxp/loxp mice with extensive cyst formation and regression of urothelial hyperplasia.

Back to article page